04:23 PM EST, 11/11/2025 (MT Newswires) -- VVT Med ( VVTMF ) , after trade Tuesday, announced key milestones in its global expansion, sales growth, and capital structure plans.

The company said it entered into a five-year distribution agreement with Medworks India for its ScleroSafe device, used to treat varicose veins. Per the deal, Medworks will buy C$3.7 million worth of units over the contract period. The device was approved by India's Central Drugs Standard Control Organisation in 2022.

In Europe, VVT Med ( VVTMF ) has reached an important clinical milestone through its exclusive representative, Promedika, by completing 150 ScleroSafe procedures in North Macedonia. "This number of procedures provides meaningful evidence of efficacy under the product's European Union CE certification and marks an important step toward broader adoption across the European Economic Area," the company said.

To strengthen its capital structure, VVT Med ( VVTMF ) plans to issue 320,000 shares with a deemed price of C$0.56 each as compensation for advisory services rendered by certain consultants in connection with its public listing. The company also intends to settle up to C$720,197 of debt by issuing 1.7-million shares at C$0.31 per share.

Both issuances are subject to approval by the TSX Venture Exchange. The completion of the debt settlement depends on final agreements and regulatory approval, the company added.

The company's shares closed down $0.02 to $0.28 on the TSX Venture Exchange.